Join or Renew With AARP for Just $16 a Year
- Discounts on travel and everyday savings
- Subscription to AARP The Magazine
- A voice in Washington and in your community
- Free membership for your spouse or partner
An experimental treatment for Alzheimer’s disease has turned out to be a disappointment in the first finished late-stage study, manufacturer Pfizer said Monday. Called bapineuzumab, it’s one of three Alzheimer’s treatments currently in clinical trials that some have been calling our “last hope” for drugs that slow the progression of the disease.